Repligen's Endostatin B (platelet factor-4)
Executive Summary
INDs for the recombinant angiogenesis inhibitor product will be filed this year for treatment of Kaposi's sarcoma and the neutralization of heparin following cardiopulmonary bypass surgery, President Sanford Smith reported Jan. 8 at the Hambrecht & Quist health care conference. Repligen says the Kaposi's indication "may get a fast track at FDA." The company estimates that nearly all 600,000 bypass patients annually would be candidates for Endostatin.